The Korean Journal of Pain

The Korean Pain Society (대한통증학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy of Glycopyrrolate in Primary Hyperhidrosis Patients

  • Lee, Hyun-Ho (Department of Anesthesiology and Pain Medicine, Ajou University College of Medicine) ;
  • Kim, Do-Won (Department of Anesthesiology and Pain Medicine, Ajou University College of Medicine) ;
  • Kim, Do-Wan (Department of Anesthesiology and Pain Medicine, Ajou University College of Medicine) ;
  • Kim, Chan (Kichan Pain clinic)
  • Received : 2011.09.30
  • Accepted : 2011.12.16
  • Published : 2012.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Primary hyperhidrosis is a disorder of excessive sweating, which shares several features with anxiety disorders and has a negative impact on a patient's quality of life. Oral glycopyrrolate is one of the treatments available. There are a few published studies on the use of glycopyrrolate given orally in the treatment of hyperhidrosis. Methods: Thies is study was a review of case notes in a series of 36 patients with primary hyperhidrosis. We made a comparison between the Keller's scale score of a pre-glycopyrrolate medication group and the Keller's scale score f a post-glycopyrrolate medication group. The Milanez de Campos score, Short Form_36 (SF-36) score, Beck Depression Inventory (BDI) score, Beck Anxiety Inventory (BAI) score, and autonomic nervous system (ANS) scale score were also compared between the two groups. Results: In the post-glycopyrrolate medication group, there were declines in Keller's scale, and Milanez de Campos scale score and BAI score (P < 0.001). In addition, there were increases in SF_36 score in the post-glycopyrrolate medication group (P = 0.03) However, no changes were seen in, BDI score and ANS score in the post-glycopyrrolate medication group (P < 0.001). Conclusions: Glycopyrrolate is an effective initial method of treating primary hyperhidrosis that, reduces anxiety and improve patients' quality of life.

Keywords

References

  1. Henteleff HJ, Kalavrouziotis D. Evidence-based review of the surgical management of hyperhidrosis. Thorac Surg Clin 2008; 18: 209-16.
  2. Klaber M, Catterall M. Treating hyperhidrosis. Anticholinergic drugs were not mentioned. BMJ 2000; 321: 703.
  3. Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. BMJ 2001; 323: 596-9.
  4. Kim WO, Yoon DM, Kil HK, Kim JI, Choi BI. Effect of oral glycopyrrolate in essential hyperhidrosis. Korean J Anesthesiol 2004; 46: 298-301.
  5. Craven JL, Rodin GM, Littlefield C. The Beck Depression Inventory as a screening device for major depression in renal dialysis patients. Int J Psychiatry Med 1988; 18: 365-74.
  6. Leyfer OT, Ruberg JL, Woodruff-Borden J. Examination of the utility of the Beck Anxiety Inventory and its factors as a screener for anxiety disorders. J Anxiety Disord 2006; 20: 444-58.
  7. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247-63.
  8. Ro KM, Cantor RM, Lange KL, Ahn SS. Palmar hyperhidrosis: evidence of genetic transmission. J Vasc Surg 2002; 35: 382-6.
  9. Ruchinskas R. Hyperhidrosis and anxiety: chicken or egg? Dermatology 2007; 214: 195-6.
  10. Bugmann P, Robert J, Magistris M, Le Coultre C. Thoracoscopic sympathectomy using ultrasonic coagulating shears: a technical improvement in the treatment of palmar hyperhidrosis. Pediatr Surg Int 2002; 18: 746-8.
  11. Reisfeld R. One-year follow-up after thoracoscopic sympathectomy for hyperhidrosis. Ann Thorac Surg 2007; 83: 358-9.
  12. Adams BB, Vargus-Adams JN, Franz DN, Kinnett DG. Hyperhidrosis in pediatric spinal cord injury: a case report and gabapentin therapy. J Am Acad Dermatol 2002; 46: 444-6.
  13. Wollina U, Karamfilov T, Konrad H. High-dose botulinum toxin type A therapy for axillary hyperhidrosis markedly prolongs the relapse-free interval. J Am Acad Dermatol 2002; 46: 536-40.
  14. Ali-Melkkila T, Kanto J, Iisalo E. Pharmacokinetics and related pharmacodynamics of anticholinergic drugs. Acta Anaesthesiol Scand 1993; 37: 633-42.

Cited by

  1. Efficacy and safety of topical glycopyrrolate in patients with facial hyperhidrosis: a randomized, multicentre, double-blinded, placebo-controlled, split-face study vol.29, pp.2, 2015, https://doi.org/10.1111/jdv.12518
  2. Elevated Social Stress Levels and Depressive Symptoms in Primary Hyperhidrosis vol.9, pp.3, 2014, https://doi.org/10.1371/journal.pone.0092412
  3. Pharmacometrics-guided drug development of antihyperhidrosis agents vol.55, pp.11, 2015, https://doi.org/10.1002/jcph.536
  4. Safety of available and emerging drug therapies for hyperhidrosis vol.16, pp.9, 2017, https://doi.org/10.1080/14740338.2017.1354983
  5. Oral glycopyrrolate after the failure of oral oxybutynin in the treatment of primary hyperhidrosis vol.176, pp.3, 2017, https://doi.org/10.1111/bjd.14876
  6. Axillary hyperhidrosis: a focused review vol.28, pp.7, 2017, https://doi.org/10.1080/09546634.2017.1309347
  7. Treatment of primary hyperhidrosis with oral anticholinergic medications: a systematic review vol.31, pp.6, 2017, https://doi.org/10.1111/jdv.14081
  8. A case report: Glycopyrrolate for treatment of exercise-induced hyperhidrosis vol.5, pp.2050-313X, 2017, https://doi.org/10.1177/2050313X17721601
  9. The relationship between preoperative psychological evaluation and compensatory sweating vol.13, pp.1, 2018, https://doi.org/10.1186/s13019-018-0728-3
  10. Interventions for hyperhidrosis in secondary care: a systematic review and value-of-information analysis vol.21, pp.80, 2017, https://doi.org/10.3310/hta21800
  11. Glicopirrolato en el tratamiento de la hiperhidrosis primaria. Cuándo y cómo vol.33, pp.2, 2012, https://doi.org/10.1016/j.piel.2017.07.004
  12. Review of oral anticholinergics in the treatment of palmoplantar hyperhidrosis vol.5, pp.2, 2019, https://doi.org/10.4103/ijdd.ijdd_40_18
  13. Current and emerging treatments targeting the neuroendocrine system for disorders of the skin and its appendages vol.29, pp.9, 2012, https://doi.org/10.1111/exd.14145
  14. Stepwise treatment of primary focal hyperhidrosis with aluminum chloride hexahydrate lotion (20%) and oral glycopyrrolate: a retrospective study from a tertiary care center vol.33, pp.6, 2012, https://doi.org/10.1111/dth.13914
  15. Survival study of treatment adherence by patients given oral glycopyrrolate for hyperhidrosis following treatment failure with oral oxybutynin vol.33, pp.6, 2012, https://doi.org/10.1111/dth.14210
  16. Adjusting oral glycopyrrolate medication for hyperhidrosis to reflect seasonal temperature variations vol.33, pp.6, 2012, https://doi.org/10.1111/dth.14249